Cetera Investment Advisers Grows Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Cetera Investment Advisers grew its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 16.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,182 shares of the medical device company's stock after purchasing an additional 10,385 shares during the quarter. Cetera Investment Advisers' holdings in DexCom were worth $5,614,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of DXCM. Private Trust Co. NA increased its holdings in shares of DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after buying an additional 245 shares during the last quarter. Optiver Holding B.V. acquired a new stake in shares of DexCom during the 4th quarter worth approximately $33,000. TD Private Client Wealth LLC increased its holdings in shares of DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after buying an additional 167 shares during the last quarter. Larson Financial Group LLC increased its holdings in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after buying an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC acquired a new stake in shares of DexCom during the 4th quarter worth approximately $38,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of recent analyst reports. Canaccord Genuity Group raised their price target on shares of DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Barclays raised their price target on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a report on Monday, May 5th. Piper Sandler cut their price target on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Citigroup lifted their target price on shares of DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a report on Tuesday, March 4th. Finally, Morgan Stanley lifted their target price on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a report on Friday, February 14th. Five analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $98.11.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Jereme M. Sylvain sold 7,000 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $73.83, for a total value of $516,810.00. Following the completion of the transaction, the executive vice president now owns 135,482 shares of the company's stock, valued at $10,002,636.06. This trade represents a 4.91% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Michael Jon Brown sold 13,000 shares of DexCom stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $914,940.00. Following the sale, the executive vice president now directly owns 105,602 shares of the company's stock, valued at approximately $7,432,268.76. This trade represents a 10.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 66,926 shares of company stock valued at $4,734,384 in the last 90 days. Company insiders own 0.32% of the company's stock.

DexCom Stock Up 1.7%

DXCM stock traded up $1.48 during midday trading on Monday, hitting $86.96. The company's stock had a trading volume of 2,366,347 shares, compared to its average volume of 4,356,667. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $132.09. The firm has a market capitalization of $34.10 billion, a P/E ratio of 60.81, a PEG ratio of 2.30 and a beta of 1.43. The firm has a 50-day simple moving average of $72.33 and a 200-day simple moving average of $77.80.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The business had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. During the same period in the prior year, the business earned $0.32 EPS. The business's quarterly revenue was up 12.5% on a year-over-year basis. As a group, equities analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.